Bisfosfonat (Romanian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bisfosfonat" in Romanian language version.

refsWebsite

Global rank Romanian rank

10nih.gov

4^th place

8doi.org

2^nd place

3^rd place

1web.archive.org

1^st place

1nos.org.uk

low place

1mhra.gov.uk

low place

doi.org

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010). „American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis”. Endocr Pract. 16 Suppl 3: 1–37. doi:10.4158/ep.16.s3.1. PMC 4876714 . PMID 21224201.
„Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society”. Menopause. 17 (1): 25–54; quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID 20061894.
Compston J, Bowring C, Cooper A, et al. (august 2013). „Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013”. Maturitas. 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID 23810490.
Allen, CS; Yeung, JH; Vandermeer, B; Homik, J (5 octombrie 2016). „Bisphosphonates for steroid-induced osteoporosis”. The Cochrane Database of Systematic Reviews. 10: CD001347. doi:10.1002/14651858.CD001347.pub2. PMC 6461188 . PMID 27706804.
Eriksen EF, Díez-Pérez A, Boonen S (ianuarie 2014). „Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review”. Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID 24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (decembrie 2013). „Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis”. Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID 24063695.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (ianuarie 2013). „European guidance for the diagnosis and management of osteoporosis in postmenopausal women”. Osteoporos Int. 24 (1): 23–57. doi:10.1007/s00198-012-2074-y. PMC 3587294 . PMID 23079689.
Weinstein RS, Roberson PK, Manolagas SC (ianuarie 2009). „Giant osteoclast formation and long-term oral bisphosphonate therapy”. N. Engl. J. Med. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022 . PMID 19118304.

mhra.gov.uk

„Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements Article date: March 2014”. MHRA.

nih.gov

ncbi.nlm.nih.gov

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010). „American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis”. Endocr Pract. 16 Suppl 3: 1–37. doi:10.4158/ep.16.s3.1. PMC 4876714 . PMID 21224201.
„Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society”. Menopause. 17 (1): 25–54; quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID 20061894.
Hauk L (august 2013). „ACOG releases practice bulletin on osteoporosis”. Am Fam Physician. 88 (4): 269–75. PMID 23944732.
Compston J, Bowring C, Cooper A, et al. (august 2013). „Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013”. Maturitas. 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID 23810490.
Allen, CS; Yeung, JH; Vandermeer, B; Homik, J (5 octombrie 2016). „Bisphosphonates for steroid-induced osteoporosis”. The Cochrane Database of Systematic Reviews. 10: CD001347. doi:10.1002/14651858.CD001347.pub2. PMC 6461188 . PMID 27706804.
Eriksen EF, Díez-Pérez A, Boonen S (ianuarie 2014). „Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review”. Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID 24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (decembrie 2013). „Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis”. Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID 24063695.
Gauthier, K; Bai, A; Perras, C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (februarie 2012). „Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms”. Rapid Response Report: Systematic Review. PMID 24278999.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (ianuarie 2013). „European guidance for the diagnosis and management of osteoporosis in postmenopausal women”. Osteoporos Int. 24 (1): 23–57. doi:10.1007/s00198-012-2074-y. PMC 3587294 . PMID 23079689.
Weinstein RS, Roberson PK, Manolagas SC (ianuarie 2009). „Giant osteoclast formation and long-term oral bisphosphonate therapy”. N. Engl. J. Med. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022 . PMID 19118304.

nos.org.uk

National Osteoporosis Society. „Drug Treatment”. U.K. National Osteoporosis Society. Arhivat din original la 6 noiembrie 2012. Accesat în 7 august 2012.

web.archive.org

National Osteoporosis Society. „Drug Treatment”. U.K. National Osteoporosis Society. Arhivat din original la 6 noiembrie 2012. Accesat în 7 august 2012.